Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05321251

Recruitment Status : Recruiting

First Posted : April 11, 2022

Last Update Posted : February 3, 2023

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

University of Alberta

Study Description

Brief Summary:

Many diseases can affect corneal nerves. Corneas that lack normal sensation are considered neurotrophic. Neurotrophic corneas are predisposed to persistent epithelial defects, recurrent erosions, and corneal ulcers. These can lead to a variety of complications, from subjective pain, discomfort, and blurry vision, to corneal perforation and endophthalmitis. Neurotrophic corneas and the persistent epithelial defects associated with them can be very difficult to treat. Non-invasive measures include topical drops (artificial tears, antibiotics, or steroids), bandage contact lens, and punctal plugs. More invasive surgical treatments include membrane grafts, tarsorrhaphy, and keratoplasty. Despite these treatments, many neurotrophic corneas still do not heal. This study aims to test the efficacy of topical insulin in the treatment of neurotrophic keratopathy.

Condition or disease	Intervention/treatment	Phase
Neurotrophic Keratitis	Drug: Insulin Procedure: Tarsorrhaphy	Phase 2 Phase 3

Show detailed description

Detailed Description:

Purpose: To trial topical insulin drops to promote healing in neurotrophic keratitis that has been refractory to conventional management versus tarsorrhaphy.

Hypothesis: Topical insulin might promote re-epithelialization in the setting of neurotrophic keratitis (Stage 2 or 3) with persistent epithelial defect refractory to conventional treatments and be a non-inferior treatment to tarsorrhaphy.

Justification: Several experiments support the use of insulin for the promotion of corneal epithelial healing. In vitro experiments with immortalized corneal epithelial cells suggest that insulin improves epithelial cell migration. A rabbit model showed improvement in corneal hypoesthesia after topical insulin exposure. These results suggest that early hypoesthesia may be reversible, and thereby improve epithelial wound healing. Another rabbit model showed that topical insulin might alter the corneal surface by increasing the tensile strength of corneal wounds. Finally, the presence of insulin receptors on the cornea and lacrimal gland suggests that insulin may contribute to corneal wound healing.

Few case studies describe the use of topical insulin in the absence of other concurrent treatments for neurotrophic keratitis.

Objectives: Through use of topical insulin, promotion of corneal healing in cases where conventional methods have failed. These include topical antibiotics, preservative free artificial tears, and bandage contact lens for at least 2 weeks. This study will evaluate topical insulin as a salvage treatment in patients who otherwise would require tarsorrhaphy.

Research Method: Patients will be recruited in Vancouver, Edmonton, Toronto, Ottawa, Halifax, and Montreal. Patients with neurotrophic corneal ulcers will be identified through the Ophthalmology on call resident clinics in each location and directly referred to a physician in their city who is participating in this study. At least 12 patients will be enrolled in each group (as per power calculation).

Baseline demographic information will be collected (age, gender, medical comorbidities, ocular comorbidities, current medications, and previous and current eyedrops). Baseline ocular examination will consist of a complete ophthalmologic exam, including visual acuity, intraocular pressure, dilated fundus exam or BScan imaging, corneal sensation, eyelid measurements (palpebral fissure, presence of entropion or ectropion, and lagophthalmos), and anterior segment exam and photography. Corneal sensation will be measured in group quadrants and centrally and quantified with cochet bonnet esthesiometry.

Patients will be randomized to one of two groups: Permanent medial tarsorrhaphy or topical insulin drops.

Patients will stop all other topical medication before commencing use of insulin eyedrops. Topical insulin will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye.

Patients will be followed up every 3 days after initiation of therapy, or as needed. Each follow up visit will include an ophthalmologic exam with repeat measurements of the epithelial defect, visual acuity, IOP, and anterior segment exam.

The primary outcome will be time to re-epithelialization of neurotrophic ulcer, defined as <0.5mm of remaining epithelial defect. There will also be an evaluation of the percentage of patients healed at each follow up time point. Subgroup analysis will analyze time to re-epithelialization in patients with diabetes separate from patients without diabetes.

The trial will be terminated early if the patients should develop adverse side effects, including allergy, worsening of symptoms, infection, or worsening of keratitis.

Plan for Data Analysis: Statistical analysis to determine the rate of improvement of neurotrophic keratitis by photograph analysis, corneal sensation in four quadrants and centrally, and visual acuity testing.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	60 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	This will be a randomized controlled trial for the treatment of neurotrophic keratitis. Topical insulin drops will be compared to the current gold standard treatment temporary tarsorrhaphy. Patients will be recruited in Vancouver, Edmonton, Toronto, Montreal, and Halifax. Patients with neurotrophic corneal ulcers will be identified through the Ophthalmology on call resident clinics in each location. They will be directly referred to a physician in their city who is participating in this study. At least 12 patients will be enrolled in each group (as per power calculation): topical insulin drops or tarsorrhaphy.
Masking:	None (Open Label)
Masking Description:	Treatment will be randomized / assigned randomly, but neither the patients, care providers, or investigators will be masked to treatment once it is being provided.
Primary Purpose:	Treatment
Official Title:	Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.
Actual Study Start Date :	June 1, 2022
Estimated Primary Completion Date :	January 2024
Estimated Study Completion Date :	January 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Keratitis-ichthyosis-deafness syndrome

Drug Information available for: Insulin Insulin human

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Topical insulin Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye. A bottle of topical insulin can be used for 14 days. Any remaining topical insulin will be discarded as waste after 14 days.	Drug: Insulin see arm description
Active Comparator: Tarsorrhaphy Patients in this group will receive a temporary, central tarsorrhaphy and will not use additional eye drops.	Procedure: Tarsorrhaphy see arm description

Arm

Intervention/treatment

Experimental: Topical insulin

Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%). Topical insulin will be administered four times per day to the affected eye. A bottle of topical insulin can be used for 14 days. Any remaining topical insulin will be discarded as waste after 14 days.

Drug: Insulin

see arm description

Active Comparator: Tarsorrhaphy

Patients in this group will receive a temporary, central tarsorrhaphy and will not use additional eye drops.

Procedure: Tarsorrhaphy

see arm description

Outcome Measures

Primary Outcome Measures :

Time to re-epithelialization of neurotrophic ulcer [ Time Frame: 3 months ]
Time taken for re-epithelialization of the neurotrophic ulcer which will be defined as <0.5 mm of the remaining epithelial defect

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of neurotrophic keratitis with persistent epithelial defect that has been refractory to conventional treatments for at least 2 weeks
18 years or older
Able to provide informed consent
Failed other conventional treatments for neurotrophic keratitis
Understanding and accepting of use of topical insulin alone

Exclusion Criteria:

Less than 18 years old
Pregnant or breastfeeding women
Unable to provide informed consent
Unable to comply with tests/follow-up
Lid function abnormalities (e.g., lagophthalmos, entropion, ectropion, or abnormal orbicularis function from cranial nerve 7 palsy or Bell's palsy)
Patients who require ongoing topical treatment (e.g. topical ganciclovir)

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05321251

Contacts

Layout table for location contacts

Contact: Maya Tong, MD	780 735 5013	mayatong@ualberta.ca
Contact: Christopher J Rudnisky, MD MPH	780 735 5013	crudnisk@ualberta.ca

Locations

Layout table for location information

Canada, Alberta
University of Alberta	Recruiting
Edmonton, Alberta, Canada, T6G 2C8
Contact: Christopher Rudnisky, MD
Canada, British Columbia
University of British Columbia	Not yet recruiting
Vancouver, British Columbia, Canada
Contact: Sonia Yeung, MD
Canada, Nova Scotia
Dalhousie University	Not yet recruiting
Halifax, Nova Scotia, Canada
Contact: Darrell Lewis, MD
Canada, Ontario
Precision Cornea Clinic	Not yet recruiting
Ottawa, Ontario, Canada
Contact: Saama Sabeti, MD
University of Toronto	Not yet recruiting
Toronto, Ontario, Canada
Contact: Clara Chan, MD
Canada, Quebec
University of Montreal	Not yet recruiting
Montréal, Quebec, Canada
Contact: Mona Dagher, MD

Sponsors and Collaborators

University of Alberta

Investigators

Layout table for investigator information

Principal Investigator:	Christopher J Rudnisky, MD MPH	University of Alberta

More Information

Publications of Results:

Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, Struck MC. Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea. 2017 Nov;36(11):1426-1428. doi: 10.1097/ICO.0000000000001297.

Other Publications:

Galvis V, Nino CA, Tello A, Grice JM, Gomez MA. Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma. Arch Soc Esp Oftalmol (Engl Ed). 2019 Feb;94(2):100-104. doi: 10.1016/j.oftal.2018.06.003. Epub 2018 Jul 17. English, Spanish.

Bastion ML, Ling KP. Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients. Med J Malaysia. 2013 Jun;68(3):208-16.

Fai S, Ahem A, Mustapha M, Mohd Noh UK, Bastion MC. Randomized Controlled Trial of Topical Insulin for Healing Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Asia Pac J Ophthalmol (Phila). 2017 Sep-Oct;6(5):418-424. doi: 10.22608/APO.201780. Epub 2017 Aug 22.

Tong CM, Iovieno A, Yeung SN. Topical insulin for neurotrophic corneal ulcers. Can J Ophthalmol. 2020 Oct;55(5):e170-e172. doi: 10.1016/j.jcjo.2020.04.001. Epub 2020 May 13. No abstract available.

Diaz-Valle D, Burgos-Blasco B, Gegundez-Fernandez JA, Garcia-Caride S, Puebla-Garcia V, Pena-Urbina P, Benitez-Del-Castillo JM. Topical insulin for refractory persistent corneal epithelial defects. Eur J Ophthalmol. 2021 Sep;31(5):2280-2286. doi: 10.1177/1120672120958307. Epub 2020 Sep 21.

Layout table for additonal information

Responsible Party:	University of Alberta
ClinicalTrials.gov Identifier:	NCT05321251
Other Study ID Numbers:	Pro00107280
First Posted:	April 11, 2022 Key Record Dates
Last Update Posted:	February 3, 2023
Last Verified:	April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No
Product Manufactured in and Exported from the U.S.:	No

Keywords provided by University of Alberta:


topical insulin neurotrophic keratopathy neurotrophic keratitis tarsorrhaphy

Additional relevant MeSH terms:

Layout table for MeSH terms

Keratitis Corneal Diseases Eye Diseases	Insulin Hypoglycemic Agents Physiological Effects of Drugs

To Top